Current medical therapy for ulcerative colitis

World Journal of Gastroenterology

Volumn 5, Issue 1, 1999, Pages 64-72

  Xu, Chang Tai ^a   Pan, Bo Rong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colitis, ulcerative drug therapy; Cyclosporin; Glucocorticosteroids; Inflammatory bowel diseases drug therapy; Sulphasalazine 5 aminosalicylic acids

Indexed keywords

EID: 0001921136     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v5.i1.64     Document Type: Review

References (31)

1. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ, 1989;298:82 -86
2. Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am Fam Physician, 1998;57:57-68, 71-72
3. Bresci G, Parisi G, Gambardella L, Banti S, Bertoni M, Rindi G, Capria A. Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up. Int J Clin Pharmacol Res, 1997;17:17-22
4. Ardizzone S, Porro GB. A practical guide to the management of distal ulcerative colitis. Drugs, 1998;55:519-542
5. Marion JF, Present DH. The modern medical management of acute, severe ulcerative colitis. Eur J Gastroenterol Hepatol, 1997;9:831-835
6. Martinsson T, Haegerstrand A, Dalsgaard CJ. Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro. Inflamm Res, 1997;46:398-403
7. Leiper K, London IJ, Rhodes JM. Management of the first presentation of severe acute colitis. Baillieres Clin Gastroenterol, 1997;11:129-151
8. Finnie IA, Campbell BJ, Taylor BA, Milton JD, Sadek SK, Yu LG, Rhodes JM. Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Clin Sci Colch, 1996;91:359-364
9. Hanauer SB. Inflammatory bowel disease. N Engl J Med, 1996;334:841-848
10. Scholmerich J. Immunosuppressive treatment for refractory ulcerative colitis - where do we stand and where are we going? Eur J Gastroenterol Hepatol, 1997; 9:842-849
11. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut, 1997;40:775-781
12. Pruitt R, Katz S, Bayless T, Levine J. Repeated use of budesonide enema is safe and effective for the treatment of acute flares of distal ulcerative colitis. Gastroenterology, 1996;110:A995
13. Van-Gossum A, Schmit A, Adler M, Chioccioli C, Fiasse R, Louwagie P, D' Haens G, Rutgeerts P, De-Vos M, Reynaert H, Devis G, Belaiche J, Van-Outryve M. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg, 1997;60:197-200
14. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med, 1993;118:540-549
15. Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology, 1998;114:15-22
16. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ, 1955;2:1041-1048
17. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW, Donlop SP. Predicting outcome in severe ulcerative colitis. Gut, 1996; 38:905-910
18. Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs, 1991;41:647-664
19. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA. Transdermal nicotine for active ulcerative colitis. N Engl J Med, 1994;330:811-815
20. Motley RJ, Rhodes J, Kay S, Morris TJ. Late presentation of ulcerative colitis in ex-smokers. Int J Colorectal Dis, 1988;3:171-175
21. Gionchetti P, Venturi A, Rizzello F, Corbelli C, Fanti S, Ferretti M, Boschi S, Miglioli M, Campieri M. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther, 1997;11: 679-684
22. Walker AM, Szneke P, Bianchi LA, Field LG, Sutherland LR, Dreyer NA. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol, 1997;92:816-820
23. Kam L, Cohen H, Dooley C, Rubin P, Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol, 1996;91:1338-1342
24. Green JT, Thomas GA, Rhodes J, Williams GT, Evans BK, Russell MA, Feyerabend C, Rhodes P, Sandborn WJ. Nicotine enemas for active ulcerative colitis - a pilot study. Aliment Pharmacol Ther, 1997;11:895-863
25. Garey KW, Streetman DS, Rainish MC. Azathioprine hypersensitivity reaction in a patient with ulcerative colitis. Ann Pharmacother, 1998;32:425-428
26. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther, 1997;11;853-858
27. Travis SP, Tysk C, de-Silva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut, 1994;35:1282-1286
28. Pena AS, Crusius JB. Genetics of inflammatory bowel disease: implications for the future. World J Surg, 1998;22:390-393
29. Robinson M. Optimizing therapy for inflammatory bowel disease. Am J Gastroenterol, 1997;92(12 Suppl):12S-17S
30. Rask-Madsen J. From basic science to future medical options for treatment of ulcerative colitis. Eur J Gastroenterol Hepatol, 1997;9:864-871
31. Rhodes J, Thomas G, Evans BK. Inflammatory bowel disease management. Some thoughts on future drug developments. Drugs, 1997;53:189-194